Literature DB >> 15924524

Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases.

Raphael Serreau1, Dominique Luton, Marie-Alice Macher, Anne-Lise Delezoide, Catherine Garel, Evelyne Jacqz-Aigrain.   

Abstract

OBJECTIVE: Angiotensin II type 1 receptor antagonists (ARA). Interacted with the renin-angiotensin system, and the present study was undertaken to examine their fetal and neonatal toxicity when taken by the mother during pregnancy.
DESIGN: Prospective follow up of pregnant women exposed to an ARA during early pregnancy.
SETTING: The present study was conducted in the departments of Paedriatric Pharmacology of the University hospital Robert Debre in Paris, France. POPULATION: Ten women exposed to an ARA during early pregnancy.
METHODS: Prospective follow up. MAIN OUTCOME MEASURE: Fetal ultrasonography and outcome of pregnancy.
RESULTS: Prenatal ultrasonography showed abnormal features in five cases (oligoamnios related to fetal tabular dysgenesis, fetal dysmorphia and renal abnormalities). Outcome of pregnancy was as follows: three induced abortions, two stillbirths (twin pregnancy), one neonate presenting with dysmorphia and renal disease and five neonates with an uneventful development.
CONCLUSION: Women of reproductive age should be advised of the possible hazards of ARA and treatment should be stopped as soon as pregnany has been documented.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15924524     DOI: 10.1111/j.1471-0528.2004.00525.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  7 in total

1.  Taking angiotensin-converting enzyme inhibitors during pregnancy: is it safe?

Authors:  Almundher Al-Maawali; Asnat Walfisch; Gideon Koren
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

Review 2.  Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review.

Authors:  Chisa Shimada; Rina Akaishi; Kazutoshi Cho; Mamoru Morikawa; Yosuke Kaneshi; Takahiro Yamda; Hisanori Minakami
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

3.  A Case of a Pregnant Woman With Primary Aldosteronism and Superimposed Preeclampsia Treated With Esaxerenone.

Authors:  Kaoru Yamashita; Satoshi Morimoto; Yuko Inoue; Kiyotaka Hirata; Shihori Kimura; Yasufumi Seki; Kanako Bokuda; Daisuke Watanabe; Atsuhiro Ichihara
Journal:  J Endocr Soc       Date:  2022-05-29

4.  Prenatal hypocalvaria after prolonged intrauterine exposure to angiotensin II receptor antagonists.

Authors:  Marine Lallemant; Sarah Prévost; François Nobili; Didier Riethmuller; Rajeev Ramanah; Marie-France Seronde; Nicolas Mottet
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Oct-Dec       Impact factor: 1.636

Review 5.  Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs-Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers.

Authors:  Paweł Bryniarski; Katarzyna Nazimek; Janusz Marcinkiewicz
Journal:  Int J Mol Sci       Date:  2022-02-04       Impact factor: 5.923

6.  Endothelium-dependent relaxation and angiotensin II sensitivity in experimental preeclampsia.

Authors:  Anne Marijn van der Graaf; Marjon J Wiegman; Torsten Plösch; Gerda G Zeeman; Azuwerus van Buiten; Robert H Henning; Hendrik Buikema; Marijke M Faas
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

7.  Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats.

Authors:  Tae Hwan Kim; Min Gi Kim; Soyoung Shin; Yong-Ha Chi; Soo-Heui Paik; Joo-Han Lee; Sun Dong Yoo; Yu Seok Youn; Jürgen B Bulitta; Sang Hoon Joo; Seok Won Jeong; Kwon-Yeon Weon; Beom Soo Shin
Journal:  BMC Pharmacol Toxicol       Date:  2016-07-26       Impact factor: 2.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.